Clinical trial · Observational

Establishment and Clinical Application of Risk Classification Model Based on Molecular Typing of Medulloblastoma in Children

NCT05406947CI-TRIAL-00063730not yet recruitingClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

The purpose of this study:(1) Development of a new risk classification model for childhood medulloblastoma. (2) Evaluation and improvement of existing individualized treatment protocols.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Medulloblastoma, Childhood	Childhood Medulloblastoma	ONTOLOGY_EXACT	0.98

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
Prospective observational study, no intervention	Other	—	UNRESOLVED

Design

Arms and outcomes

Arms (3)

label
Low risk group
description
Based on clinicopathological diagnosis and molecular pathological diagnosis, the children were classified into low risk groups, individualized radiotherapy and chemotherapy plan was made, and a perfect registration and follow-up system was established.
interventionNames
1. Other: Prospective observational study, no intervention
label
Middle risk group
description
Based on clinicopathological diagnosis and molecular pathological diagnosis, the children were classified into middle risk groups, individualized radiotherapy and chemotherapy plan was made, and a perfect registration and follow-up system was established.
interventionNames
1. Other: Prospective observational study, no intervention
label
High risk group
description
Based on clinicopathological diagnosis and molecular pathological diagnosis, the children were classified into high risk groups, individualized radiotherapy and chemotherapy plan was made, and a perfect registration and follow-up system was established.

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 6 Months
Maximum age: 18 Years

Show eligibility criteria text

Inclusion Criteria:

* Age 0.5-18 years (except neonates).
* Pathologically confirmed medulloblastoma.
* Not having received any other relevant treatment before surgery.
* Completion of enhanced MRI of the head and spinal cord.
* Availability of tumor samples and determination of molecular typing.
* Postoperative KPS score ≥ 70.
* Voluntary enrollment in the group and the ability to receive long-term follow-up.
* The patient or the patient's family voluntarily signed the informed consent form.

Exclusion Criteria:

* Patients who have recently received other drugs or radiation therapy.
* Patients suffering from acute or chronic infectious diseases
* Patients suffering from neurological or psychiatric diseases or mental disorders that cannot be easily controlled, or poor compliance.
* Patients who cannot receive enhanced MRI scans.
* Other conditions that the investigator believes make the patient unfit to participate in this trial.

References

Publications (0)

Data not yet available

No reference posted for this study.